Skip to content
Screener

Immunovant, Inc. IMVT Business Segments — Share-Based Payment Arrangement, Expense

Similar metrics at other companies

Concentrix Corporation logo
CNXCReportable Segment — Share-Based Payment Arrangement, Expense
$25.37M-5.6%
LPR
LPROReportable Segment — Share-Based Payment Arrangement, Expense
$1.06M-39.1%
Concentra Group Holdings Parent logo
CONReportable Segment — Share-Based Payment Arrangement, Expense
$4.14M+82.2%
GRAIL, Inc. logo
GRALReportable Segment — Share-Based Payment Arrangement, Expense
$18.91M+37.5%
Dine Brands Global logo
DINRental Segment — Share-Based Payment Arrangement, Expense
$0
Dine Brands Global logo
DINFranchise Segment — Share-Based Payment Arrangement, Expense
$1.1M+10.0%

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.21B+201%
Enterprise value$7.31B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:28 AM EDT
Fiscal year
FY2026
Accession
0001764013-26-000064
Line itemYears Ended March 31, 2026Years Ended March 31, 2025Years Ended March 31, 2024
Research and development expenses$29,527$27,014$20,409
General and administrative expenses25,36522,44920,604
Total stock-based compensation$54,892$49,463$41,013

Item 8. Financial Statements and Supplementary Data

FAQ

What is Immunovant, Inc.'s business segments — share-based payment arrangement, expense?
Immunovant, Inc. (IMVT) reported business segments — share-based payment arrangement, expense of $6.28M in Q1 2026.
How has Immunovant, Inc.'s business segments — share-based payment arrangement, expense changed year-over-year?
Immunovant, Inc.'s business segments — share-based payment arrangement, expense decreased by 2.9% year-over-year, from $6.47M to $6.28M.
What is the long-term trend for Immunovant, Inc.'s business segments — share-based payment arrangement, expense?
Over 3 years (2023 to 2026), Immunovant, Inc.'s business segments — share-based payment arrangement, expense has grown at a 22.9% compound annual growth rate (CAGR), from $17.49M to $32.49M.
What does business segments — share-based payment arrangement, expense mean?
Represents the non-cash compensation expense recognized for equity-based awards granted to employees and directors within the segment. This metric reflects the cost of aligning the interests of the workforce with shareholders through stock options or restricted stock units. It is essential for understanding the true economic cost of human capital and potential shareholder dilution.

Ask your AI about Immunovant, Inc.'s business segments — share-based payment arrangement, expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude